Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity Post author: Post published:December 1, 2023 Post category:uncategorized The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption. You Might Also Like New guidelines can help alleviate unnecessary referrals related to unexpected bleeding July 10, 2024 New mother’s experience highlights importance of postpartum heart care March 27, 2026 Egypt achieves historic malaria-free certification October 21, 2024